BPR3P0128

Overview

BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase ( RdRp ) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC 50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir ( HY-104077 ).

Application

Products | Products > Disease Areas > Viral Infection | Products > Disease Areas > hCoV-229E | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-161356
• CAS No.: 1345406-09-8
• Molecular Formula: C22H18BrN3O2
• Molecular Weight: 436.30
• Purity: 98.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source